INmune Bio (INMB) - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45782T1051
INmune Bio, Inc. is a clinical-stage immunology company working on shifting the patient's natural immune system to address cancer and neurodegenerative illnesses. Their goal is to create and bring to market treatment options for blood cancers, solid tumors, and persistent inflammation.
The company's innovative programs include INKmune, developed to aid women with relapse refractory ovarian carcinoma solid tumor and individuals with high-risk myelodysplastic syndrome. Moreover, INB03 targets patients with cancers expressing MUC4, a significant marker of resistance to immunotherapy such as HER2+ breast cancer, showcasing promise in managing MUC4 resistant cancers.
XPro1595 represents another vital development for INmune Bio, focusing on treating Alzheimer's disease and Treatment Resistant Depression, offering hope and potential breakthroughs in these challenging conditions. Additionally, the company holds license agreements with key entities like Xencor, Inc., Immune Ventures, LLC, and the University of Pittsburgh.
Founded in 2015 and headquartered in Boca Raton, Florida, INmune Bio, Inc. is committed to transforming the landscape of immunology with cutting-edge treatments. To learn more about their groundbreaking work, visit their website at https://www.inmunebio.com.
Drawdown (Underwater) Chart
INMB Stock Overview
| Market Cap in USD | 190m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC SubIndustry | Biotechnology |
| TER | 0.00% |
| IPO / Inception | 2019-02-04 |
INMB Stock Ratings
| Growth 5y | 1.06 |
| Fundamental | - |
| Dividend | - |
| Rel. Performance vs Sector | 3.82 |
| Analysts | 4.67/5 |
| Fair Price Momentum | 10.24 USD |
| Fair Price DCF | - |
INMB Dividends
| Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
INMB Growth Ratios
| Growth 12m | 47.22% |
| Growth Correlation 12m | 36% |
| Growth Correlation 3m | -53% |
| CAGR 5y | 1.17% |
| Sharpe Ratio 12m | 0.55 |
| Alpha vs SP500 12m | 11.32 |
| Beta vs SP500 5y weekly | 1.44 |
| ValueRay RSI | 67.59 |
| Volatility GJR Garch 1y | 75.50% |
| Price / SMA 50 | -0.98% |
| Price / SMA 200 | 15.22% |
| Current Volume | 130.7k |
| Average Volume 20d | 176.2k |
External Links for INMB Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of May 03, 2024, the stock is trading at USD 11.13 with a total of 130,735 shares traded.
Over the past week, the price has changed by +2.68%, over one month by +1.64%, over three months by +0.45% and over the past year by +44.92%.
According to ValueRays Forecast Model, INMB INmune Bio will be worth about 11.5 in May 2025. The stock is currently trading at 11.13. This means that the stock has a potential upside of +3.32%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 19.7 | 76.7 |
| Analysts Target Price | 17.3 | 55.7 |
| ValueRay Target Price | 11.5 | 3.32 |